Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13224
UPID:
NMDE2_HUMAN
Alternative names:
Glutamate [NMDA] receptor subunit epsilon-2; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3
Alternative UPACC:
Q13224; Q12919; Q13220; Q13225; Q14CU4; Q9UM56
Background:
The Glutamate receptor ionotropic, NMDA 2B, known alternatively as Glutamate [NMDA] receptor subunit epsilon-2, plays a pivotal role in neural communication, acting as a component of NMDA receptor complexes. These complexes are crucial for synaptic plasticity and memory formation, functioning as heterotetrameric, ligand-gated ion channels with high calcium permeability.
Therapeutic significance:
Linked to Intellectual developmental disorder, autosomal dominant 6, and Developmental and epileptic encephalopathy 27, the protein's modulation offers a promising avenue for therapeutic intervention. Understanding the role of Glutamate receptor ionotropic, NMDA 2B could open doors to potential therapeutic strategies.